CALCIFIC SUPRASPINATUS TENDINITIS
Conditions
Interventions
Trade Name: Cimetidine 200mg (Cemidine 200mg)
Product Name: Cimetidine 200mg
Pharmaceutical Form: Tablet
INN or Proposed INN: cimetidine
Sponsors
University Hospitals of Leicester NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.A clinical and radiologic diagnosis of calcific supraspinatus tendinitis. 2.A painful shoulder of sufficient severity to warrant Orthopaedic referral. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Patients who refuse to consent or are unable to give informed consent. 2.Patients who are unable to complete the self-administered questionnaire. 3.Patients who have had previous surgery to their shoulder. 4.Patients who have already had aspiration and needling therapy for their calcific tendinitis. 5.Patients already on Cimetidine or other H2 receptor blocker. 6.Patients with history of allergy or adverse reaction to Cimetidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: TO ASSESS WHETHER CIMETIDINE 200mg B.D HASTENS THE RADIOLOGICAL RESOLUTION OF THE CALCIFICATION IN THE SUPRASINATUS TENDON.;Secondary Objective: TO ASSESS WHETHER CIMETIDINE 200mg B.D HASTENS THE RESOLUTION OF THE PAIN AND DISABILITY OF SUPRASPINATUS CALCIFIC TENDINITIS.;Primary end point(s): Completion of the 3 month course of Cimetidine or placebo. All patients will be followed up in routine clinics until final discharge. | — |
Countries
United Kingdom
Outcome results
None listed